CONCLUSIONS
Our cohort demonstrates the real-world outcome of GCTs treated at a
developing country with emphasis on challenges that come along with it.
The low and intermediate risk tumors had an excellent outcome, thus
warranting a gradual shift in the approach to these tumors by reducing
therapy and decreasing late effects of therapy. In high risk GCTs
however, intensifying therapies to improve outcomes must be balanced
against the risk of toxic deaths and cumulative toxicity.
CONFLICTS OF INTEREST: None
ACKNOWLEDGEMENTS: The authors wish to acknowledge the
assistance of Ms. Smruti Mokal, Biostatistician at the Clinical Research
Secretariat (CRS), Tata Memorial Hospital.